ANNOUNCEMENT

Save $300 on MedCity CONVERGE Healthcare Innovation Summit July 9-10 in Philadelphia. Earlybird rate ends May 20.

Topic: Sanofi

Sanofi plans regulatory filings for myelofibrosis drug treatment after successful drug trial

Sanofi plans regulatory filings for myelofibrosis drug treatment after successful drug trial

May 18, 2013 10:00 am by | 0 Comments

PARIS (Reuters) - French drugmaker Sanofi said a late-stage Phase III trial of a drug designed to treat myelofibrosis led to positive results.Myelofibrosis is a rare, life-threatening condition that involves ... Read more
Sanofi agrees to reorganize Toulouse research site, not close it

Sanofi agrees to reorganize Toulouse research site, not close it

May 17, 2013 8:19 am by | 0 Comments

PARIS (Reuters) - Sanofi said it would overhaul rather than exit its Toulouse research site, as it seeks to break an impasse with the French government which opposed the drugmaker's ... Read more
Sanofi recruits patients for arthritis trials

Sanofi recruits patients for arthritis trials

May 15, 2013 1:35 am by | 0 Comments

PARIS (Reuters) - French drugmaker Sanofi SA said it and U.S. firm Regeneron Pharmaceuticals have started recruiting patients for two new trials of their arthritis treatment sarilumab.The drug is seen ... Read more
Sanofi first quarter misses forecasts on patent losses

Sanofi first quarter misses forecasts on patent losses

May 2, 2013 2:41 am by | 0 Comments

PARIS (Reuters) - Sanofi reported lower-than-expected first-quarter earnings on Thursday as the effects of last year's patent losses and foreign exchange headwinds crimped growth from diabetes drugs, vaccines and rare ... Read more
Sanofi infant vaccine gets EU approval

Sanofi infant vaccine gets EU approval

April 22, 2013 1:41 am by | 0 Comments

PARIS (Reuters) - French drug maker Sanofi SA said on Monday the European Commission has approved its primary and booster vaccine for infants from six weeks of age.The vaccine protects ... Read more
Sanofi’s multiple sclerosis treatment Aubagio could be copied in Europe within 3 years

Sanofi’s multiple sclerosis treatment Aubagio could be copied in Europe within 3 years

March 25, 2013 4:10 am by | 0 Comments

LONDON (Reuters) - Uncertainty over European exclusivity for Sanofi's new multiple sclerosis (MS) pill Aubagio could disrupt the wider market and impact other companies, according to a leading industry analyst.The ... Read more
Drugmakers eye Africa’s middle classes as next growth market

Drugmakers eye Africa’s middle classes as next growth market

February 12, 2013 2:30 am by | 0 Comments

For pharmaceutical companies, Africa is changing.

Not only is the continent's economic growth grabbing attention in boardrooms but the shifting nature of its disease burden is luring Big Pharma, as new ... Read more

FDA head and company CEOs cheer bumper haul of new drugs

FDA head and company CEOs cheer bumper haul of new drugs

January 25, 2013 1:33 pm by | 0 Comments

* Approvals in past 2 years "cause for optimism" -FDA head* Scientific progress, better diagnostics help productivity* Pick-up follows lean period for drug industry R&D labsDAVOS, Switzerland, Jan 25 (Reuters) ... Read more
EMA rejects Sanofi, Isis cholesterol drug due to safety concerns, side effects

EMA rejects Sanofi, Isis cholesterol drug due to safety concerns, side effects

December 14, 2012 7:52 am by | 0 Comments

LONDON (Reuters) - European regulators on Friday recommended against approval of Sanofi and Isis Pharmaceutical's drug Kynamro for treatment of a rare genetic disorder that causes unusually high cholesterol.The European ... Read more
EMA approves two Sanofi drugs, including new diabetes treatment GLP-1 analogue

EMA approves two Sanofi drugs, including new diabetes treatment GLP-1 analogue

November 16, 2012 7:51 am by | 0 Comments

LONDON (Reuters) - Sanofi won the backing of European regulators for two new drugs against diabetes and cancer on Friday, a shot in the arm for the French company's drive ... Read more
French newspaper says Sanofi considered moving headquarters to America or England

French newspaper says Sanofi considered moving headquarters to America or England

November 4, 2012 8:49 am by | 0 Comments

PARIS (Reuters) - Sanofi's management considered moving its headquarters abroad in the last few months but the plan was nixed by the drugmaker's chairman, French weekly Le Journal du Dimanche ... Read more
The Lancet criticizes Sanofi for cost of Lemtrada, withdrawal of Campath

The Lancet criticizes Sanofi for cost of Lemtrada, withdrawal of Campath

October 31, 2012 8:03 pm by | 0 Comments

PARIS (Reuters) - Medical journal The Lancet warned that Sanofi's experimental multiple sclerosis drug Lemtrada may be too costly for patients and health insurers once it gets approved by regulators.The ... Read more
Sanofi sees some relief from patent loss pain

Sanofi sees some relief from patent loss pain

October 25, 2012 4:31 am by | 0 Comments

PARIS (Reuters) - French drugmaker Sanofi forecast 2012 earnings would fall less than expected as cost cuts and demand for diabetes and rare disease drugs cushion the blow from patent ... Read more
FDA panel recommends Sanofi, Isis drug Kynamro for rare disorder

FDA panel recommends Sanofi, Isis drug Kynamro for rare disorder

October 18, 2012 3:04 pm by | 0 Comments

WASHINGTON (Reuters) - A U.S. Food and Drug Administration panel of outside experts on Thursday recommended Sanofi SA's and Isis Pharmaceutical Inc's drug, Kynamro, for treatment of a rare genetic ... Read more
FDA reviewers say Sanofi, Isis lipid drug may increase the risk of cancer

FDA reviewers say Sanofi, Isis lipid drug may increase the risk of cancer

October 16, 2012 2:51 pm by | 0 Comments

(Reuters) - U.S. drug reviewers flagged several safety concerns, including possible cancer risks, related to Sanofi SA and Isis Pharmaceuticals Inc's lipid disorder drug Kynamro, sending Isis's shares down as ... Read more